Brainomix Overview
Pro stress-test →Brainomix, a spinout from the University of Oxford, has revolutionized medical imaging with an AI-powered platform that automates validated imaging biomarkers—improving both diagnosis and treatment decisions. The company's flagship product, Brainomix 360 Stroke, has been deployed to more than 300 hospitals and used in over 1.5 million patient cases across more than 20 countries. The platform has been associated with a 50% increase in the number of patients receiving mechanical thrombectomy, a procedure that can substantially reduce post-stroke disability.
Strategic Profile
Pro stress-test →Brainomix has built its commercial position on a body of clinical evidence that is unusual for an AI imaging company at this stage. New guidance from NICE, the globally respected health assessor, endorses the use of Brainomix 360 Stroke, with Brainomix being one of only two companies granted this highly coveted endorsement. The company is expanding beyond stroke into new therapeutic areas with similar unmet needs—harnessing AI to transform diagnosis and treatment where it matters most.
Competitive Landscape
Pro stress-test →Brainomix competes in the AI-powered medical imaging and stroke care decision-support space against companies developing similar diagnostic imaging solutions. Key competitors include vendors of radiology AI platforms and stroke imaging tools, though Brainomix differentiates through its comprehensive clinical validation evidence, NICE endorsement, FDA clearances, and demonstrated real-world impact on patient outcomes. The company's expansion into pulmonary fibrosis imaging positions it against broader medical imaging AI vendors.
Industry Context
Brainomix operates in Medical imaging AI software.
Key facts
Founded: 2010 · Headquarters: Oxford, United Kingdom · Employees: 51-200